205 related articles for article (PubMed ID: 12431473)
1. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Wåhlander K; Lapidus L; Olsson CG; Thuresson A; Eriksson UG; Larson G; Eriksson H
Thromb Res; 2002 Aug; 107(3-4):93-9. PubMed ID: 12431473
[TBL] [Abstract][Full Text] [Related]
2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
3. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
4. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
5. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
6. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
[TBL] [Abstract][Full Text] [Related]
9. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
[TBL] [Abstract][Full Text] [Related]
10. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
Gustafsson D; Elg M
Thromb Res; 2003 Jul; 109 Suppl 1():S9-15. PubMed ID: 12818629
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Cullberg M; Eriksson UG; Wåhlander K; Eriksson H; Schulman S; Karlsson MO
Clin Pharmacol Ther; 2005 Apr; 77(4):279-90. PubMed ID: 15903126
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
13. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
Wernevik LC; Nyström P; Andersson M; Johnsson G; Bylock A; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):85-94. PubMed ID: 16430313
[TBL] [Abstract][Full Text] [Related]
14. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG
J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746
[TBL] [Abstract][Full Text] [Related]
19. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]